In Q2FY25, Medanta's performance was above our expectations. Recorded highest-ever revenue of INR 9,566 mn, showing a growth of 13.3% YoY and 11.1% QoQ, driven by higher patient volumes, increase in bed occupied days, and improvements in realization. The ARPOB for matured hospitals grew by 6.2% YoY to INR 67,059, while for developing hospitals, it declined by 5.9% YoY to INR 53,724. Occupancy for developed hospitals came in at 67%, compared to 65% last year, whereas for developing hospita...
Hold Global Health Ltd For Target Rs. 1,146 By Choice Broking Ltd
In Q1FY25, Medanta's performance was below expectations. Revenue reached INR 8,611 mn, showing a growth of 11.4% YoY and 6.5% QoQ. The ARPOB for matured hospitals grew by 3.2% YoY to INR 67,160, while for developing hospitals, it declined by 1.7% QoQ to INR 58,205. Occupancy for developed hospitals came in at 63%, compared to 60% last year, whereas for developing hospitals, it was 52% versus 54% last year. Consolidated EBITDA increased by 4.7% YoY and 3.9% QoQ to INR 1,863 mn. However, th...
Buy Global Health Ltd For Target Rs.1,246 By Choice Broking Ltd
On robust runway for sustainable growth
* Over the past four years, MEDANTA has delivered a stupendous performance (3x earnings), witnessing a 35% EBITDA CAGR. Moreover, it turned net cash in FY23 from a net debt of INR3b in FY19. Since listing in 3QFY23, the stock has more than doubled today.
* Interestingly, over FY23-26E, the outlook remains strong, on the back of a healthy pipeline of beds being added to the existing facilities (552 beds) and the upcoming ones in Noida, Indore, and ...
Buy Global Health Ltd For Target Rs.1,170 - Motilal Oswal Financial Services Ltd
